Evidence map›Paper›PMID 26423798›Full record

ArticleImmunology2015

A vaccine formulated with the major outer membrane protein can protect C3H/HeN, a highly susceptible strain of mice, from a Chlamydia muridarum genital challenge.

Sukumar Pal, Olga V Tatarenkova, Luis M de la Maza

Open access · bronzeAbstract read
In one paragraph

Article in Immunology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.8field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Soluble antigens derived fromCell reports. Medicine · 2021
    Article
  5. Vaccines · 2021
    Article
  6. Article
  7. Expert review of vaccines · 2021
    Article
  8. Article
  9. Article
  10. TheFrontiers in immunology · 2018
    Article
  11. Update on Chlamydia trachomatis Vaccinology.Clinical and vaccine immunology : CVI · 2017
    Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Sukumar PalDepartment of Pathology and Laboratory Medicine, Medical Sciences I, University of California, Irvine, Irvine, CA, USA.
Olga V TatarenkovaDepartment of Pathology and Laboratory Medicine, Medical Sciences I, University of California, Irvine, Irvine, CA, USA.
Luis M de la MazaDepartment of Pathology and Laboratory Medicine, Medical Sciences I, University of California, Irvine, Irvine, CA, USA.
University of California, Irvine Medical Center · US

Funding

IMMUNOPATHOLOGY OF TUBAL INFERTILITYR01AI032248 · NIAID · UNIVERSITY OF CALIFORNIA-IRVINE · PI DE LA MAZA, LUIS M · 1993 to 2007
$2.6M
Trapping membrane proteins with adjuvant-carrying amphipols for vaccine formulatiR01AI092129 · NIAID · UNIVERSITY OF CALIFORNIA-IRVINE · PI COCCO, MELANIE J, DE LA MAZA, LUIS M · 2011 to 2014
$1.3M
Neonatal immunity against C. trachomatis infectionsR21AI064853 · NIAID · UNIVERSITY OF CALIFORNIA-IRVINE · PI PAL, SUKUMAR · 2008 to 2009
$420k
NIAID NIH HHS AI-032248NIAID NIH HHS AI-092129NIAID NIH HHS R01 AI032248NIAID NIH HHS R01 AI092129NIAID NIH HHS R21 AI064853
6 · The paper itself

Abstract

C3H/HeN female mice were vaccinated with native Chlamydia muridarum major outer membrane protein (MOMP), using Montanide+CpG or Alum+CpG as adjuvants. Negative control groups were immunized with ovalbumin (OVA) and the same adjuvants. As positive control, mice were inoculated intranasally with live Chlamydia. Mice were challenged in the ovarian bursa with 10(5) C. muridarum inclusion forming units. Six weeks after the genital challenge the animals were caged with male mice and monitored for pregnancy. Mice vaccinated with MOMP+Montanide+CpG developed high levels of C. muridarum-specific antibodies, with a high IgG2a/IgG1 ratio and neutralizing titres. Animals immunized using Alum+CpG had low antibody levels. Cellular immune responses were significantly higher in mice vaccinated with MOMP and Montanide+CpG, but not with Alum+CpG, when compared with negative controls. Following the genital challenge, only 20% (4/20) of mice vaccinated with MOMP+CpG+Montanide had positive vaginal cultures whereas 100% (9/9) of mice immunized with MOMP+CpG+Alum had positive cultures. Of the positive control animals inoculated with live Chlamydia only 15% (3/20) had positive vaginal cultures. In contrast, 100% (20/20) of mice immunized with OVA+CpG+Montanide, or minimal essential medium, had positive cultures. Following mating, 80% (16/20) of mice vaccinated with MOMP+CpG+Montanide, and 85% (17/20) of animals inoculated intranasally with live C. muridarum carried embryos in both uterine horns. No protection against infertility was observed in mice immunized with MOMP and CpG+Alum or OVA. In conclusion, this is the first time that a subunit vaccine has been shown to elicit a protective immune response in the highly susceptible C3H/HeN strain of mice against an upper genital challenge.

Indexed as

AnimalsAntibodies, BacterialBacterial Outer Membrane ProteinsBacterial VaccinesChlamydia InfectionsChlamydia muridarumDisease Models, AnimalDisease SusceptibilityFemaleFertilityGenital Diseases, FemaleImmunity, CellularMaleMiceMice, Inbred C3HOvaryAntibodies, BacterialBacterial Outer Membrane ProteinsBacterial VaccinesVaccines, SubunitadjuvantsChlamydia muridarumimmunizationmajor outer membrane proteinmice

Identifiers

PMID26423798
PMCPMC4610632
OpenAlexW1883815693

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.